The first antibiotic with artificial intelligence technology

Artificial intelligence continues to astound us in various fields, and its latest achievement was the invention of a new antibiotic that can eliminate powerful bacteria.

How was this accomplished?

According to a recent study published in the journal Nature Biotechnology, researchers have developed a new antibiotic using artificial intelligence technology that can overcome deadly and drug-resistant bacterial infections.

The results of this study revealed a new antibiotic called "Abaucin" that can kill a type of strong bacteria known as "Acinetobacter baumannii."

This dangerous bacteria is resistant to antibiotics and can cause wound infections and lead to pneumonia, often found in hospitals.

The researchers explained that they used artificial intelligence technology after training it initially to evaluate the effectiveness of compounds in inhibiting bacterial growth.

Data for approximately 6,680 new compounds were inputted, and the artificial intelligence program was able to exclude thousands of them and select a few potential ones with efficacy. What's remarkable is that artificial intelligence took less than two hours to select these compounds, which is very short compared to the much longer time researchers would typically require to complete this process.

The researchers then selected 240 compounds from those chosen by artificial intelligence for practical application.

The results showed the effectiveness of nine of these compounds, with "Abaucin" being the most effective and potent in eliminating "Acinetobacter baumannii" bacteria in wounds when tested on infected mice.

In addition to these promising results, the researchers noted that the antibiotic developed through artificial intelligence can eliminate powerful bacteria without affecting beneficial bacteria in the body.

This indicates that "Abaucin" is very precise and may prevent the development of resistance, potentially having fewer side effects.

The researchers leading this study pointed out that the next step is to conduct extensive testing of "Abaucin" and carry out clinical trials, with the drug expected to be available to patients by 2030.

This innovation is considered a potentially revolutionary step in the field of medicine and science, and it may help discover other antibiotics to combat resistant bacteria and save many lives.